Viatris, the generics and branded medicines maker created by Pfizer in 2020, has entered a definitive agreement to acquire Pacira BioSciences for $1.65 billion, or $36.50 per share in cash — a steep premium over the $25.20 closing price the day before the announcement. Pacira shares rallied 44.4% after the news, according to Zacks via TradingView. Both boards unanimously approved the deal, which is expected to close by the end of 2026 via a tender offer followed by a second-step merger. Viatris plans to fund the purchase primarily with excess cash, with the remainder from short-term borrowings, and says it expects minimal impact on its gross leverage ratio. Cravath Swaine & Moore is advising Viatris while Ashurst Perkins Coie represents Pacira, per Law360.

Pacira brings two marketed, patent-protected, high-margin pain drugs: Exparel, an injectable bupivacaine liposome formulation approved in 2011 for post-surgical pain, which generated $291.1 million in net sales in the first half of 2026 per Zacks, and Zilretta, an extended-release injectable corticosteroid for osteoarthritis knee pain, which brought in $59.4 million in the same period. Together the pair generated $350.5 million in first-half product sales. Viatris also acquires Pacira's 340-person U.S. commercial team, market access and medical affairs capabilities, and its most advanced pipeline asset, PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy in phase II development for osteoarthritis of the knee, with Part A data of the ASCEND study expected by year-end.

The timing is tied to Viatris' own pipeline: the FDA is scheduled to rule by Dec. 27, 2026 on Viatris' filing for a fast-acting meloxicam (FAM) formulation, a novel non-opioid treatment for moderate-to-severe acute pain. Viatris sees FAM serving the at-home market while Exparel and Zilretta cater to inpatients and outpatients respectively — yet all three would be prescribed by the same post-surgical and high-volume acute pain specialists. Oppenheimer suggested Exparel during surgery and FAM after surgery could be offered as one opioid-sparing package, if FAM's label supports it, calling that the main revenue synergy ahead of the Dec. 27 PDUFA date. Viatris projects FAM peak sales of up to $500 million and more than $50 million in cost synergies by the end of 2028, per Oppenheimer's note.

Viatris is buying despite looming generic competition. Pacira settled litigation with three companies last year, agreeing to allow some U.S. production of generic Exparel starting in early 2030, and remains in litigation with two other drugmakers seeking generic copies. Zilretta's composition-of-matter patent expires in 2031. Pacira has argued that its extensive know-how and trade secrets represent a meaningful entry barrier, and Viatris plans to apply its intellectual-property expertise and proven ability to extend product lifecycles to sustain sales after competition enters. Another lever is geography: Pacira currently generates 100% of its sales in the U.S., and Viatris plans to expand the products into select international markets, building on Pacira's existing partnership with LG Chem to bring Exparel to Asia-Pacific markets.

Completion remains subject to customary closing conditions, including tender of a majority of Pacira's outstanding shares and regulatory clearance, with closing expected by the end of 2026. Viatris says establishing U.S. commercial infrastructure through the deal will enable an 'opportunistic approach' to future business development. For investors, the stakes cut both ways: Simply Wall St pegged Viatris at $17.49 with a most-followed fair value of $19.40, suggesting the stock still looks modestly undervalued even after committing the $1.65 billion, though it faces price erosion in major markets and reliance on mature, off-patent products. Seeking Alpha upgraded Viatris from Sell to Hold, viewing the acquisition as a strategic step while cautioning that execution risks and legacy revenue declines persist.